Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Supriya Lifescience Ltd (SUPRIYA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543434 NSE: SUPRIYA Pharmaceuticals & Drugs | Small Cap | Supriya Lifescience Share Price
₹900 -18.75 (-2.04%)
As on 11-Sep'26 16:01
Supriya Lifescience Ltd (SUPRIYA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543434 NSE: SUPRIYA Pharmaceuticals & Drugs | Small Cap | Supriya Lifescience Share Price
₹900 -18.75 (-2.04%)
As on 11-Sep'26 16:01
Key Metrics
Valuation Multiples
Market Cap
₹7,394 Cr.
Current Price
₹900
52-Week Low / High
₹546 / 1,086
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.3
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
18.86%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
68.30%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹16.1 Cr.
Face Value
₹2
All Time Low / High
₹170.05 / 1085.50
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Supriya Lifescience Ltd a good quality company?
Supriya Lifescience Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Supriya Lifescience Ltd performance compare with that of its Peers?
Revenue growth of Supriya Lifescience Ltd vs industry peers?
Supriya Lifescience Ltd revenue CAGR is 16.17%, compared to the industry median CAGR of 5.76%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Supriya Lifescience Ltd?
Promoters hold 68.30% of the Supriya Lifescience Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Supriya Lifescience Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 43.7% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Supriya Lifescience Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 11.5% | 13.8% | 36.5% | 49.7% | 60.1% | 43.3% | 18.7% | 22.3% | 27.6% | 25.3% | - |
| Value Creation Index ⓘ | -0.2 | 0.0 | 1.7 | 2.7 | 3.5 | 2.1 | 0.3 | 0.6 | 1.0 | 0.9 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 828 | 873 |
| Sales YoY Gr. | - | 16% | 30.5% | 12.2% | 25.5% | 35.5% | -13% | 23.7% | 22.1% | 18.9% | - |
| Adj EPS ⓘ | 0.7 | 0.9 | 5.3 | 10.1 | 16.9 | 18.9 | 11.2 | 14.8 | 23.3 | 26 | 24.7 |
| YoY Gr. | - | 26.5% | 520.9% | 88.6% | 67.7% | 11.7% | -40.8% | 32.5% | 57.6% | 11.5% | - |
| BVPS (₹) ⓘ | 5.5 | 7.5 | 12.8 | 20.4 | 36.7 | 76.5 | 86.9 | 101.3 | 123.8 | 148.8 | 151.8 |
| Adj Net Profit ⓘ | 5 | 6.3 | 39.1 | 73.7 | 124 | 152 | 89.9 | 119 | 188 | 209 | 198 |
| Cash Flow from Ops. ⓘ | 27.3 | 27.8 | 48.9 | 116 | 75.9 | 48.8 | 63.6 | 113 | 165 | 186 | - |
| Debt/CF from Ops. ⓘ | 5.1 | 4.7 | 1.8 | 0.7 | 0.9 | 0.4 | 0.3 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 18.2% | 16.2% | 21.6% | 18.9% | ||||
| Adj EPS ⓘ | 49.9% | 9% | 32.5% | 11.5% | ||||
| BVPSⓘ | 44.2% | 32.3% | 19.6% | 20.2% | ||||
| Share Price | - | - | 44.4% | 37.8% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 11.3 | 12.5 | 52.6 | 60.7 | 59.2 | 34.3 | 13.7 | 15.7 | 20.7 | 19.1 | 16.4 |
| Op. Profit Mgn % ⓘ | 9.3 | 10.3 | 23.8 | 31.7 | 44.3 | 40.4 | 27.9 | 30.8 | 37.5 | 35.6 | 33.2 |
| Net Profit Mgn % ⓘ | 2.7 | 3 | 14.1 | 23.7 | 31.6 | 28.6 | 19.5 | 20.9 | 27 | 25.3 | 22.7 |
| Debt to Equity ⓘ | 3.5 | 2.4 | 1 | 0.6 | 0.3 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 220 | 174 | 141 | 166 | 158 | 140 | 206 | 179 | 163 | 165 | 100 |
| Cash Conv. Cycle ⓘ | 65 | 54 | 26 | 22 | 19 | 51 | 82 | 53 | 47 | 63 | 81 |
Valuation of Supriya Lifescience - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Supriya Lifescience Ltd FAQs
The current trading price of Supriya Lifescience on 11-Sep-2026 16:01 is ₹900.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Supriya Lifescience stood at ₹7,394.4 Cr
The latest P/E ratio of Supriya Lifescience as of 10-Sep-2026 is 37.27.
The latest P/B ratio of Supriya Lifescience as of 10-Sep-2026 is 6.05.
The 52-week high of Supriya Lifescience is ₹1,085.5 and the 52-week low is ₹545.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Supriya Lifescience is ₹873 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Supriya Lifescience Ltd is a below average quality company.
The key valuation ratios of Supriya Lifescience Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Supriya Lifescience Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Supriya Lifescience Ltd
The company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (RoC), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC.
The company is a global leading manufacturer of Active pharmaceutical Ingredients. The company’s pharmaceutical business is organized into domestic and export sales, according to the geographies in which it operates. It has grown its API business in several countries across Europe, Latin America, Asia (excluding India), North America and India. The company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom it has business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom it has business relationship for over four years. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA.
Business area of the company
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.
Awards, accreditations or recognitions
- 2009: Certificate of Excellence for outstanding Export Performance in the product group Chemicals, Drugs, Pharma and Allied Products (MSME) awarded by Federation of Indian Export Organisations.
- 2010: Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises, Government of India.
- 2016: Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra.
- 2016: Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra.
- 2017: Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
- 2017: Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra.
- 2019: Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India.
Major events and milestones
- 2008 Incorporation of the Company upon its conversion from a partnership firm to a public limited company.
- 2009: Started production of Ketamine Hydrochloride.
- 2010: CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate.
- 2011: IDL granted for Chlorphenamine Maleate.
- 2013: COFEPRIS and KFDA approval granted.
- 2014: USFDA approval granted
- 2014: IDL granted for Brompheniramine Maleate.
- 2015: EUGMP and EDQM approval granted.
- 2017: CEP (Certificate of Sustainability) granted for Pheniramine Maleate.
- 2017: Second time USFDA approval granted.
- 2018: CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride.
- 2020: Third time USFDA approval.
- 2021: CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate.
- 2021: NMPA approval granted.
- 2021: Health Canada approval.
You have 32 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
